Climb Bio, Inc. (CLYM) Stock

Climb Bio, Inc. (CLYM) is a Healthcare stock trading at $14.22 (as of 2026-09-11), with a market capitalization of $817.03M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Understand Climb Bio, Inc.: how it makes money

Climb Bio is developing budoprutug, an anti-CD19 antibody for autoimmune diseases including lupus nephritis and immune thrombocytopenia, with no approved commercial product. The entire investment case rests on a single lead asset advancing through late-stage clinical trials for a specific set of autoimmune indications.

Climb Bio has no revenue engine; the entire value proposition is a binary option on regulatory approval of budoprutug, with cash burn as the only current output.

Business quality (Unprofitable): Pre-revenue biotech in the clinical development phase; no commercial product, no revenue, and operating losses driven entirely by R&D spend.

Bull case

  • R&D phase drives expected losses: The operating margin of -828% reflects a company fully loaded into late-stage clinical development for budoprutug, which is the expected cost profile before any commercial revenue exists. The P&L is an R&D ledger, not a sign of structural operational dysfunction.

Bear case

  • No revenue offsets cash burn: With zero revenue and an operating margin of -828%, every dollar of spending is pure cash consumption with no commercial offset to stabilize it. The company must secure continuous external financing to reach a viable revenue milestone, making survival dependent on capital markets.
Valuation — source: SEC EDGAR (first-party)
Price$14.22
Market Cap$817.03M
Price / Book3.41
Price / Sales112.97
FCF Yield-6.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$8.32M
Net Margin-719.1%
Return on Equity-24.1%
Current Ratio31.45
Revenue Growth (YoY)-14.6%
EPS Growth (YoY)38.5%
FCF Growth (YoY)-3.7%
Financial Health — source: SEC EDGAR
Altman Z-Score53.09 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)19.4
Industry P/E (Pharmaceutical Products)15.1
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderRA CAPITAL MANAGEMENT, L.P. ($147.36M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOAoife Brennan BCh MMSc
Employees17
CountryUS
IPO Date2021-08-10

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Cullinan Therapeutics, Inc. (CGEM)
  • Vera Therapeutics, Inc. (VERA)
  • Zenas BioPharma, Inc. (ZBIO)
  • Kyverna Therapeutics, Inc. (KYTX)
  • Adicet Bio, Inc. (ACET)
  • Cabaletta Bio, Inc. (CABA)
  • Contineum Therapeutics, Inc. (CTNM)
  • Precigen, Inc. (PGEN)
CLYM earnings history · CLYM institutional & insider holders · CLYM KPIs & operating metrics · CLYM financials · CLYM filings, presentations & press releases · CLYM investor presentations & press releases · CLYM SEC filings · CLYM peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-09-11.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.